Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203482 · ClinicalTrials.gov registry record
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
A clinical trial of Prostate Cancer, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 300
- Enrollment target
- 2
- Study locations
NCT07203482 is a study of Prostate Cancer that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 300 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07203482, a study of Prostate Cancer, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this research database is to prospectively collect data to assess treatment related complications, oncologic outcomes and urinary/sexual function, and identify predictors of complications, oncological control and functional outcomes after Hhigh-intensity focused ultrasound (HIFU) ablation of prostate cancer with the intent to guide further research and improve patient care. We will include subjects who will have a HIFU procedure performed from all Sub-Investigators included in the study.
Conditions Studied
Study Locations (2)
New York
- NYU Langone Health - Cobble Hill - Brooklyn
- NYU Langone Health - Tisch Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-05-16 |
| Est. Completion | 2050-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07203482
The ClinicalTrials.gov registry entry for NCT07203482 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07203482 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07203482 about?
NCT07203482 is a clinical study titled "Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation". Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this research database is to prospectively collect data to assess treatment related complications, oncol...
What is the current status of trial NCT07203482?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-05-16. Estimated completion is 2050-12-31.
What conditions does trial NCT07203482 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT07203482?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07203482 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.